What is HC Wainwright's Estimate for NBIX FY2026 Earnings?

Key Points

• HC Wainwright has revised its estimate for Neurocrine Biosciences' FY2026 earnings per share (EPS) to $4.16, down from a previous estimate of $4.19, while maintaining a "Buy" rating and a target price of $168.00.
• The consensus estimate for Neurocrine's current full-year earnings is $4.28 per share, indicating a slight divergence in projections among analysts.
• Neurocrine Biosciences reported a quarterly earnings of $1.06 EPS, surpassing analysts' expectations of $0.98, with a revenue of $687.50 million during the same quarter.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Equities researchers at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for shares of Neurocrine Biosciences in a report issued on Thursday, July 31st. HC Wainwright analyst A. Fein now expects that the company will earn $4.16 per share for the year, down from their prior forecast of $4.19. HC Wainwright currently has a "Buy" rating and a $168.00 price objective on the stock. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share. HC Wainwright also issued estimates for Neurocrine Biosciences' FY2027 earnings at $5.90 EPS and FY2028 earnings at $9.64 EPS.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.08. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%. The company had revenue of $687.50 million for the quarter, compared to analyst estimates of $653.09 million. During the same period in the previous year, the firm earned $1.63 earnings per share. Neurocrine Biosciences's revenue for the quarter was up 16.5% compared to the same quarter last year.

Several other equities analysts also recently commented on NBIX. Stifel Nicolaus increased their price target on Neurocrine Biosciences from $166.00 to $174.00 and gave the company a "buy" rating in a report on Thursday, July 31st. The Goldman Sachs Group started coverage on shares of Neurocrine Biosciences in a research note on Thursday, July 10th. They issued a "buy" rating and a $182.00 target price on the stock. BMO Capital Markets increased their target price on shares of Neurocrine Biosciences from $96.00 to $115.00 and gave the stock a "market perform" rating in a research report on Tuesday, May 6th. Piper Sandler raised their target price on Neurocrine Biosciences from $154.00 to $175.00 and gave the company an "overweight" rating in a research note on Thursday, July 31st. Finally, Wall Street Zen raised Neurocrine Biosciences from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 2nd. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $160.90.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX traded down $3.37 during mid-day trading on Monday, reaching $125.07. The company had a trading volume of 436,730 shares, compared to its average volume of 1,288,079. The stock has a market capitalization of $12.40 billion, a PE ratio of 37.10, a price-to-earnings-growth ratio of 0.92 and a beta of 0.25. Neurocrine Biosciences has a twelve month low of $84.23 and a twelve month high of $154.87. The stock's 50 day moving average is $128.64 and its 200-day moving average is $120.74.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of hedge funds have recently made changes to their positions in NBIX. Dodge & Cox lifted its stake in shares of Neurocrine Biosciences by 83.5% in the 1st quarter. Dodge & Cox now owns 5,534,624 shares of the company's stock valued at $612,129,000 after purchasing an additional 2,518,199 shares during the period. Wellington Management Group LLP grew its stake in Neurocrine Biosciences by 44.0% in the first quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company's stock valued at $232,037,000 after acquiring an additional 640,556 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Neurocrine Biosciences by 2.9% in the 4th quarter. AQR Capital Management LLC now owns 1,896,891 shares of the company's stock worth $258,926,000 after purchasing an additional 53,610 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Neurocrine Biosciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 1,875,062 shares of the company's stock valued at $255,523,000 after buying an additional 15,830 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in Neurocrine Biosciences by 3.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,539,601 shares of the company's stock worth $170,281,000 after purchasing an additional 49,088 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 9,613 shares of the business's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $120.38, for a total value of $1,157,212.94. Following the completion of the sale, the director owned 514,596 shares of the company's stock, valued at $61,947,066.48. The trade was a 1.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Ingrid Delaet sold 457 shares of the stock in a transaction that occurred on Thursday, July 10th. The stock was sold at an average price of $135.00, for a total value of $61,695.00. Following the sale, the insider directly owned 4,730 shares in the company, valued at $638,550. This represents a 8.81% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 90,251 shares of company stock worth $11,672,602. Corporate insiders own 4.80% of the company's stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.